Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN4A | P35499 | 2/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.41 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17512684 | 1.00 | SCN4A (0.43) | SCN4AGAAS1PR1S1PR5ALDH1A1 | |
| SCHEMBL17512685 | 1.00 | SCN4A (0.43) | SCN4AGAAS1PR1S1PR5ALDH1A1 | |
| SCHEMBL17512598 | 1.00 | SCN4A (0.43) | SCN4AGAAS1PR1S1PR5ALDH1A1 | |
| SCHEMBL17512558 | 0.88 | ARG1 (0.42) | SCN4AGAAS1PR1S1PR5ALDH1A1 | |
| SCHEMBL17512557 | 0.88 | ARG1 (0.42) | SCN4AGAAS1PR1S1PR5ALDH1A1 | |
| SCHEMBL17512704 | 0.76 | S1PR1 (0.43) | SCN4AGAAS1PR1S1PR5 | |
| SCHEMBL7315782 | 0.69 | DPP4 (0.53) | GAA | |
| SCHEMBL1717591 | 0.69 | GAA (0.46) | GAAS1PR1S1PR5ALDH1A1CYP2D6 | |
| SCHEMBL17512663 | 0.68 | ACHE (0.46) | GAACYP2D6 | |
| SCHEMBL17512541 | 0.68 | ACHE (0.46) | GAACYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11197867-B2 | Aminopyrimidinyl compounds | PFIZER INC. (US) | 2021-12-14 | — | — | US | disclosed |
| US-20210377495-A1 | AMINOPYRIMIDINYL COMPOUNDS | PFIZER INC. (US) | 2021-12-02 | — | — | US | disclosed |
| US-10980815-B2 | Aminopyrimidinyl compounds | PFIZER INC. (US) | 2021-04-20 | — | — | US | disclosed |
| US-20200330477-A1 | AMINOPYRIMIDINYL COMPOUNDS | PFIZER INC. (US) | 2020-10-22 | — | — | US | disclosed |
| US-20200038409-A1 | AMINOPYRIMIDINYL COMPOUNDS | PFIZER INC. (US) | 2020-02-06 | — | — | US | disclosed |
| US-10463675-B2 | Aminopyrimidinyl compounds | PFIZER INC. (US) | 2019-11-05 | — | — | US | disclosed |
| EP-3183247-B9 | AMINOPYRIMIDINYL COMPOUNDS AS JAK INHIBITORS | PFIZER (US) | 2018-07-25 | — | — | EP | disclosed |
| EP-3183247-B1 | AMINOPYRIMIDINYL COMPOUNDS AS JAK INHIBITORS | PFIZER (US) | 2017-11-29 | — | — | EP | disclosed |
| US-20170239264-A1 | AMINOPYRIMIDINYL COMPOUNDS | PFIZER INC. (US) | 2017-08-24 | — | — | US | disclosed |
| EP-3183247-A1 | AMINOPYRIMIDINYL COMPOUNDS AS JAK INHIBITORS | Pfizer Inc (US) | 2017-06-28 | — | — | EP | disclosed |
| US-9663526-B2 | Aminopyrimidinyl compounds | PFIZER INC. (US) | 2017-05-30 | — | — | US | disclosed |
| US-20160052930-A1 | AMINOPYRIMIDINYL COMPOUNDS | PFIZER INC. (US) | 2016-02-25 | — | — | US | disclosed |
| WO-2016027195-A1 | AMINOPYRIMIDINYL COMPOUNDS AS JAK INHIBITORS | PFIZER INC. (US) | 2016-02-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.